By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German molecular diagnostics company Epigenomics today announced flat revenues for the first quarter year over year while its net loss rose 12 percent.

For the three months ended March 31, Epigenomics said that revenues stayed at €621,000 ($888,300), with product sales and commercial R&D activities generating €166,000 and licensing deals generating €455,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.